HHS Directs FDA to Halt Enforcement on Six Unapproved Peptides

The Department of Health and Human Services published a new policy on Wednesday directing the Food and Drug Administration not to act against specialty pharmacies that sell six specific wellness peptides. The move grants legal protection to injectable compounds including BPC-157, TB-500, and KPV, which are currently promoted for muscle building, injury healing, and energy enhancement. Under existing FDA rules, these chemicals are considered illegal drugs because they have not completed the agency's rigorous review process for safety and effectiveness.

Health Secretary Robert F. Kennedy Jr. spearheaded the policy, stating in a posted document that the change advances patient choice and freedom while protecting the public from unscreened ingredients often found in online sales. Kennedy has previously described himself as a big fan of peptides and noted that he used BPC-157 to treat a muscle injury. The policy represents a shift from HHS's original plan, which sought a formal FDA regulation adding these substances to a list of safe compounding ingredients.

FDA scientific staffers opposed the decision, warning that it undermines the agency's long-standing mission to keep unproven health products off the U.S. market. Six people familiar with the development told The Associated Press that the agency’s scientists had little input on the final decision. After FDA officials expressed major safety concerns about deeming the peptides safe, HHS officials shifted their approach to direct the FDA simply not to enforce its rules against pharmacies that compound the substances.

Dr. Peter Lurie, who leads the Center for Science in the Public Interest, criticized the timing of the change, noting it occurred days before the midterm election. Lurie, a former FDA official, described the move as a wink and nod to the Make America Healthy Again faithful in the hope that they would show up at the polls. He argued that diverting patients from rigorously tested drugs for conditions like insomnia and anxiety toward these unproven compounds would lead to more unnecessary pain and suffering.

Lee Rosebush of the American Academy of Peptide Medicine reacted favorably to the news. In an online post, he stated that HHS had taken a huge step for patient and provider medical freedom. The decision aligns with the interests of major telehealth providers such as Hims & Hers, which announced plans to offer wellness peptides once the government changed its policy. Wall Street analysts estimate the peptide market could be worth more than $2 billion.

The new policy includes guardrails intended to improve safety, such as requiring pharmacies to use peptide ingredients from FDA-registered factories. Compounders are also directed to collect information on side effects for safety analysis and verify the purity of the peptides they use. However, Lurie pointed out that the FDA does not have the authority under federal law to enforce these specific pharmacy requirements. An HHS spokesperson said the agency is confronting the risks of black-market peptides by providing a more controlled alternative through licensed U.S. compounders.

Decisions regarding compounding pharmacies have historically rested with the FDA, which maintains an office dedicated to protecting consumers from unsafe compounded drugs. This oversight became a priority after a 2012 outbreak of fungal meningitis linked to contaminated injections from a Massachusetts pharmacy. Former FDA officials noted that it is extremely rare for HHS to take the lead in drafting policies for the compounding industry, though federal law technically grants HHS authority over drug regulations that are then delegated to the FDA.

In July, a panel of outside experts selected by HHS voted to drop restrictions on the six peptides named in the new documents. The panel included doctors, pharmacists, and consultants who work in the peptide field. This vote followed a meeting where FDA staffers reiterated that more than half a dozen peptides remained unproven in terms of safety and effectiveness. The policy takes effect immediately, allowing the six peptides to be sold by specialty pharmacies without the prior enforcement action that characterized their status for years.